1. OP0010 Effect of denosumab compared with risedronate in glucocorticoid-treated individuals: results from the 12-month primary analysis of a randomized, double-blind, active-controlled study. (15th June 2017) Authors: Saag, K; Wagman, RB; Geusens, P; Adachi, J; Messina, O; Emkey, R; Chapurlat, R; Daizadeh, N; Pannacciulli, N; Lems, W Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 54 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. (29th May 2019) Authors: Ferrari, S; Libanati, C; Lin, Celia Jow Fang; Brown, JP; Cosman, F; Czerwiński, E; de Gregόrio, LH; Malouf‐Sierra, J; Reginster, J‐Y; Wang, A; Wagman, RB; Lewiecki, EM Journal: Journal of bone and mineral research Issue: Volume 34:Number 6(2019) Page Start: 1033 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗